논문 상세보기

대한당뇨병학회> International Congress of Diabetes and Metabolism> S3-1 : Inflammasome modulation to treat NASH & liver fibrosis

S3-1 : Inflammasome modulation to treat NASH & liver fibrosis

Ariel Feldstein
  • : 대한당뇨병학회
  • : International Congress of Diabetes and Metabolism 2020권0호
  • : 프로시딩
  • : 2020년 09월
  • : 2-2(1pages)

DOI


목차


					

키워드 보기


초록 보기

Cell death and inflammation are two central elements in the development of liver fibrosis and injury. Inflammasomes are intracellular multiprotein complexes expressed in both hepatocytes and non-parenchymal cells in the liver that are key regulators of inflammation and cell fate. They respond to cellular danger signals by activating caspase 1, releasing the proinflammatory cytokines IL-1β and IL-18, as well as initiating a novel pathway of programmed cell death termed “pyroptosis.” This novel type of cell death is intrinsically pro-inflammatory because it is associated with the release of IL-1β and other intracellular content to the extracellular space including NLRP3 inflammasome particles that represent a novel mechanism to spread inflammasome signaling to adjacent cells. These downstream effectors of NLRP3 inlfammasome activation in the liver can initiate and perpetuate abnormal wound-healing responses with the principle cellular target being the activation of hepatic stellate cells. From the various inflammasomes, the NLRP3 inflammasome has been increasingly implicated in the pathogenesis of chronic inflammatory liver diseases, including nonalcoholic steatohepatitis, a disease process that is soaring and has evolved as a primary cause of liver fibrosis and need for liver transplantation. In this seminar, I will highlight the growing evidence for both indirect and direct effects of NRLP3 inflammasome activation in triggering liver fibrosis and its role for therapeutic intervention for treatment of Nonalcoholic Steatohepatitis (NASH).

UCI(KEPA)

간행물정보

  • : 의약학분야  > 내과학
  • :
  • :
  • : 연간
  • :
  • :
  • : 학술지
  • : 프로시딩
  • : 2011-2020
  • : 3535


저작권 안내

한국학술정보㈜의 모든 학술 자료는 각 학회 및 기관과 저작권 계약을 통해 제공하고 있습니다.

이에 본 자료를 상업적 이용, 무단 배포 등 불법적으로 이용할 시에는 저작권법 및 관계법령에 따른 책임을 질 수 있습니다.

발행기관 최신논문
| | | | 다운로드

1PL-1 : Diabetes care: post COVID-19 new normal

저자 : Kun-ho Yoon

발행기관 : 대한당뇨병학회 간행물 : International Congress of Diabetes and Metabolism 2020권 0호 발행 연도 : 2020 페이지 : pp. 1-1 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

The pandemic of coronavirus disease 2019(COVID-19) overwhelming the whole world, since the first case was reported in Wuhan, China in December 2019. As of on Aug. 8, 2020, worldwide, here have been 19,187,943 confirmed cases of COVID-19, including 716,075 deaths, reported to WHO. Although the fatality rate of COVID-19 is lower than that of SARS-CoV-1 and MERS-CoV, the absolute number of fatality in COVID-19 is extremely high because of high prevalence of COVID-19. Because of diabetes was significantly associated with worse outcomes, international diabetes associations including KDA have suggested strict glycemic control and prioritizing COVID-19 screening in elderly (aged ≥70 years) patients with diabetes to defend against COVID-19. KDA also suggest to refrain from going out or visiting crowded areas, put on a mask before visit a medical institution, avoid crowds, and avoid contacting someone with fever or respiratory symptoms. For blood sugar management, KDA suggest to make sure to keep oral medication and insulin administration more strictly than usual, conduct and check self-monitoring of blood sugar more frequently. Contact the community healthcare center is needed if there are any respiratory symptoms. If it is difficult to visit the doctor, consult through the phone helpline allowed temporarily by government. In this special COVID-19 pandemic environment, traditional way of healthcare through face-to-face contact so called analogue healthcare system might have a lot of prob-lems. It increases a chances of COVID-19 infection during clinic and hospital visit for only simple consultation or pre-scription refills and could not cover the patient's and physi-cian's needs. Modern digital healthcare system can provide pa-tients, family members, and healthcare professionals with sup-port during COVID-19 pandemic. For preparing the future another infectious disease pandemic attack, we have to prepare nationwide remote monitoring and couching system for the patients.

2S1-4 : Multiomics approach in DKD research

저자 : Nan Hee Kim

발행기관 : 대한당뇨병학회 간행물 : International Congress of Diabetes and Metabolism 2020권 0호 발행 연도 : 2020 페이지 : pp. 1-2 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Diabetes is rapidly increasing worldwide, and approximately 40% of them will develop renal complications. Diabetic kidney disease (DKD) is the leading cause of end stage renal disease, which needs significant healthcare costs and results in early death. For several decades, investigators have sought to discover inherited risk factors and biomarkers for DKD. Several genome-wide association studies (GWAS) have been conducted for DKD with further meta-analysis of GWAS and comprehensive “single gene” meta-analyses now published. Despite these efforts, much of the inherited predisposition to DKD remains unexplained. Multi-omics approach including transcriptomic, proteomic, and metabolomic studies are being used to help elucidate the unknown mechanisms and possible biomarkers in the development and progression of DKD. In this talk, I will summarize the recent progress of multi-omics studies in searching for the biomarkers of DKD. oxi

3S1-3 : Anti-diabetes drugs and GFR

저자 : Sang Soo Kim

발행기관 : 대한당뇨병학회 간행물 : International Congress of Diabetes and Metabolism 2020권 0호 발행 연도 : 2020 페이지 : pp. 1-1 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Diabetes has reached epidemic proportions in Korea and worldwide, and is associated with increased risk for chronic kidney disease (CKD) and end stage kidney disease (ESKD). The natural history of diabetic kidney disease (DKD) traditionally has been described as progressive albuminuria followed by a steady loss of glomerular filtration rate (GFR). However, the natural course of kidney function (GFR decline or trajectory) among people with diabetes (especially, type 2 diabetes) might be complex in real practice. A strong evidence demonstrated a consistent association between eGFR decline and subsequent development of hard renal endpoints (such as ESKD or renal death) from observational data and clinical trials. These data may support the use of GFR parameters (decline, changes or slope) as a surrogate endpoint for kidney disease progression in both real practice and clinical trials. Antidiabetic drugs have the potential for both benefit and harm to the kidneys and these effects play a pivotal role in patient-centered management overt DKD and. Studies on renal endpoints were also performed as pre-specified secondary outcomes in recent cardiovascular outcome trials (CVOTs). This review focuses on the clinical implication of eGFR decline as renal outcomes and the effects on renal outcomes of currently available anti-diabetic drugs.

4S1-2 : Diabetic medications and albuminuria

저자 : Soon Hyo Kwon

발행기관 : 대한당뇨병학회 간행물 : International Congress of Diabetes and Metabolism 2020권 0호 발행 연도 : 2020 페이지 : pp. 1-1 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Increased urinary albumin excretion in diabetes is associated with renal and cardiovascular disease (CVD). The reduction in albuminuria in diabetes may reduce the risk of CVD events and slow the progression of diabetic kidney disease. The effects of new antidiabetic drugs such as as sodium-glucose cotransporter 2 (SGLT-2) inhibitors, and glucagon-like peptide 1 (GLP-1) receptor agonists, on the long-term outcomes in patients with diabetes are very promising. Recent studies indicate that SGLT2 inhibitors and GLP-1 receptor agonists reduce albuminuria compared with other conventional therapies such as and dipeptidyl peptidase 4 (DPP-4) inhibitors, sulfonylurea and placebo. The reduction of albuminuria may be associated with the cardiovascular and renal beneficial effects of these medications. The mechanisms of the albuminuria reduction are under investigated. Clinicians should consider these anti-diabetic medications therapy with blood pressure and cholesterol control for protection diabetic complications.

5PL-3 : Pancreatic islet biology, function, and dysfunction: different pathways in different diabetes

저자 : Alvin C. Powers

발행기관 : 대한당뇨병학회 간행물 : International Congress of Diabetes and Metabolism 2020권 0호 발행 연도 : 2020 페이지 : pp. 1-1 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

A critical component of all forms of diabetes is reduced insulin secretion. This presentation will discuss new research that highlights different mechanisms leading to impaired islet function in human diabetes. The presentation will also discuss research approaches that are changing the understanding of the pathogenesis of islet dysfunction in type 1 and type 2 diabetes.

6PL-2 : Digital transformation of future medicine accelerated by COVID-19

저자 : Sungroh Yoon

발행기관 : 대한당뇨병학회 간행물 : International Congress of Diabetes and Metabolism 2020권 0호 발행 연도 : 2020 페이지 : pp. 1-1 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

In this talk, I will first introduce the history and key development of artificial intelligence and big data and then present how the pandemic of COVID-19 is transforming many aspects of daily life all over the globe. In addition, I will explain how the future of medicine will be affected by the technological advances driving so-called non-contact economy. I will wrap-up the presentation by introducing the presidential committee on the 4th industrial revolution I am currently chairing.

7S1-1 : SGLT2 Inhibitors and kidney protection beyond diabetes

저자 : David Z. Cherney

발행기관 : 대한당뇨병학회 간행물 : International Congress of Diabetes and Metabolism 2020권 0호 발행 연도 : 2020 페이지 : pp. 1-1 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

The objective of this lecture is to review recent advances in the cardiovascular-renal-metabolic field, with a focus on trials that have demonstrated kidney protection. The discussion will also review insights into mechanisms responsible for kidney protection in people with and without underlying diabetes. Finally, the talk will review some of the ongoing trials in this area that target unmet needs in people with kidney disease.

8S3-2 : Cholesterol in the transition from steatosis to steatohepatitis

저자 : Jose C Fernandez-checa

발행기관 : 대한당뇨병학회 간행물 : International Congress of Diabetes and Metabolism 2020권 0호 발행 연도 : 2020 페이지 : pp. 2-3 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Cholesterol is a critical component of membrane bilayers that determine their physico chemical properties. Cholesterol accumulation plays a role in the progression of metabolic liver diseases and its regulation emerges as a potential target for intervention. Cholesterol trafficking in hepatocyte mitochondria determines mitochondrial function and susceptibility to oxidative stress and inflammation-mediated cell death. Cholesterol accumulation in hepatic stellate cells and Kupffer cells plays a key role in the initiation of fibrogenesis and recruitment of inflammatory cells, contributing to the progression of steatosis to steatohepatitis.

9S3-1 : Inflammasome modulation to treat NASH & liver fibrosis

저자 : Ariel Feldstein

발행기관 : 대한당뇨병학회 간행물 : International Congress of Diabetes and Metabolism 2020권 0호 발행 연도 : 2020 페이지 : pp. 2-2 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Cell death and inflammation are two central elements in the development of liver fibrosis and injury. Inflammasomes are intracellular multiprotein complexes expressed in both hepatocytes and non-parenchymal cells in the liver that are key regulators of inflammation and cell fate. They respond to cellular danger signals by activating caspase 1, releasing the proinflammatory cytokines IL-1β and IL-18, as well as initiating a novel pathway of programmed cell death termed “pyroptosis.” This novel type of cell death is intrinsically pro-inflammatory because it is associated with the release of IL-1β and other intracellular content to the extracellular space including NLRP3 inflammasome particles that represent a novel mechanism to spread inflammasome signaling to adjacent cells. These downstream effectors of NLRP3 inlfammasome activation in the liver can initiate and perpetuate abnormal wound-healing responses with the principle cellular target being the activation of hepatic stellate cells. From the various inflammasomes, the NLRP3 inflammasome has been increasingly implicated in the pathogenesis of chronic inflammatory liver diseases, including nonalcoholic steatohepatitis, a disease process that is soaring and has evolved as a primary cause of liver fibrosis and need for liver transplantation. In this seminar, I will highlight the growing evidence for both indirect and direct effects of NRLP3 inflammasome activation in triggering liver fibrosis and its role for therapeutic intervention for treatment of Nonalcoholic Steatohepatitis (NASH).

10S2-4 : Exercise recommendations for good transition

저자 : Seung Jae Jeong

발행기관 : 대한당뇨병학회 간행물 : International Congress of Diabetes and Metabolism 2020권 0호 발행 연도 : 2020 페이지 : pp. 2-2 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Adolescence is critical periods for developing movement skills, learning healthy habits, and establishing a firm foundation for lifelong health and well-being. Regular physical activity in adolescents promotes health and fitness. Compared to inactive people, physically active teenagers have higher levels of cardiorespiratory fitness and stronger muscles. They also typically have lower body fat and stronger bones. Physical activity also has brain health benefits for school-aged children, including improved cognition and reduced symptoms of depression.
But, pediatric diabetes is a challenging condition to manage for various physiological and behavioural reasons. Regular exercise is most important, but people with type 1 diabetes tend to be as inactive as the general people. For pediatric diabetes, regular exercise can improve health and wellbeing, and can help individuals to achieve their target lipid profile, body composition, and fitness and glycaemic goals.
Exercise guidelines for teenagers with pediatric diabetes are not much different from ordinary teenagers. School-age adolescents can gain significant health benefits by engaging in moderate physical activity for a period of up to 60 minutes each day. The activities should include aerobic activities as well as activities that strengthen the muscles and bones that fit the age. . Like adults, the total amount of physical activity is more important for achieving health benefits than is any one component (frequency, intensity, or duration) or specific mix of activities (aerobic, muscle strengthening, bone strengthening). Even so, bone-strengthening activities remain especially important for young adolescents because the greatest gains in bone mass occur during the years just before and during puberty. In addition, the majority of peak bone mass is obtained by the end of adolescence.
Teenagers in pediatric diabetes who are regularly active have a better chance of a healthy adulthood.

주제별 간행물
간행물명 수록권호

KCI등재

International Journal of Thyroidology
14권 1호 ~ 14권 1호

KCI등재 SCI

Gut and Liver
15권 3호 ~ 15권 3호

KCI등재 SCI

Gut and Liver
15권 3호 ~ 15권 3호

KCI등재 SCI

Gut and Liver
15권 3호 ~ 15권 3호

KCI등재 SCI

Gut and Liver
15권 3호 ~ 15권 3호

KCI등재

대한소화기학회지
77권 5호 ~ 77권 5호

Korean Journal of Medicine(구 대한내과학회지)
96권 3호 ~ 96권 3호

KCI등재 SCI SCOUPUS

Diabetes and Metabolism Journal (DMJ)
45권 3호 ~ 45권 3호

대한내과학회 춘계학술발표논문집
2021권 0호 ~ 2021권 0호

KCI등재 SCI SCOUPUS

Journal of Neurogastroenterology and Motility
27권 2호 ~ 27권 2호

KCI등재

Allergy asthma & respiratory disease
9권 2호 ~ 9권 2호

KCI등재 SCI SCOUPUS

Clinical and Molecular Hepatology(대한간학회지)
27권 2호 ~ 27권 2호

KCI등재 SCOUPUS

Intestinal research (Intest Res)
19권 2호 ~ 19권 2호

KCI등재 SCI SCOUPUS

Endocrinology and Metabolism(구 대한내분비학회지)
36권 2호 ~ 36권 2호

KCI등재 SCI SCOUPUS

The Korean Journal of Internal Medicine
36권 3호 ~ 36권 3호

KCI등재

대한소화기학회지
77권 4호 ~ 77권 4호

당뇨병(JKD)
22권 1호 ~ 22권 1호

KCI등재 SCOUPUS

Kidney Research and Clinical Practice(구 대한신장학회지)
40권 1호 ~ 40권 1호

KCI등재 SCOUPUS

Clinical Endoscopy
54권 2호 ~ 54권 2호

KCI등재 SCI

Gut and Liver
15권 2호 ~ 15권 2호
발행기관 최신논문
자료제공: 네이버학술정보
발행기관 최신논문
자료제공: 네이버학술정보

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기